• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Palomar, Syneron settle patent spat for $31M plus royalties

Palomar, Syneron settle patent spat for $31M plus royalties

September 16, 2011 By MassDevice staff

Palomar
Syneron

Syneron Medical Ltd. (NSDQ:ELOS) agreed to pony up $31 million plus royalties for the rights to a pair of Palomar Medical Technologies (NSDQ:PMTI) patents for laser- and light-based hair removal technologies, ending a long-running legal battle.

Syneron inherited the imbroglio when it acquired Palomar’s Bay State rival, Candela Corp., for $65 million in January 2010. The case dates back to a pair of patents Burlington, Mass.-based Palomar licensed from Mass. General Hospital back in 1995 for light-based hair removal.

Palomar had accused Candela (and then Syneron) of willfully copying its technology. Today Syneron and Palomar announced a deal that will see Yokneam, Israel-based Syneron dish out $31 million in up-front cash for the rights to the two patents in the case. Syneron will also pay out royalties on sales of "consumer home-use lamp-based hair removal products," according to a press release.

Sign up to get our free newsletters delivered right to your inbox

The royalties are structured to deliver 5.0 percent "up to up to an undisclosed amount of cumulative sales," then 6.5 percent up to another secret milestone and 7.5 percent after that, according to the release. The deal also includes provisions for Palomar to license Syneron and Candela patents royalty-free. Forty percent of of all payments from the deal will go, in turn, to the General Hospital Corp., which owns Mass. General.

"Palomar pioneered the cosmetic light-based industry with the first high-powered laser hair removal system in 1997," Palomar president & CEO Joseph Caruso, said in prepared remarks. "Our intellectual property strategy has proved to be a valuable asset for our shareholders and we will continue to focus on expanding our intellectual property in the future."

“We are pleased to reach a mutually beneficial settlement that effectively ends the patent disputes between Syneron and Palomar," added Syneron CEO Louis Scafuri. "Syneron has a very strong balance sheet and we believe this fully paid-up license is a strategically beneficial utilization of our cash. It eliminates our exposure to continued legal liability in the matter, does not require any additional payments for professional hair removal systems, and supports our ongoing efforts to improve the company’s gross and operating margins.”

Filed Under: Cosmetic/Aesthetic, Legal News, News Well, Patent Infringement Tagged With: Candela Corp., Palomar Medical Technologies Inc., Syneron Medical Ltd.

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy